Aripiprazole in an Animal Model of Chronic Alcohol Consumption and Dopamine D₂ Receptor Occupancy in Rats

References

• Batel P. Addiction and schizophrenia. Eur Psychiatry 2000; 15(2):115–122.
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264:2511–2518.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2004; 172:291–297.
   PubMed Web of Science ®Google Scholar
• Heinz A. Dopaminergic dysfunction in alcoholism and schizophrenia – Psychopathological and behavioral correlates. Eur Psychiatry 2002; 17(1):9–16.
   Google Scholar
• Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour – Review of data from preclinical research. Acta Psychiatr Scand 2005; 427:14–21.
   Google Scholar
• Koob GF. Drugs of abuse: Anatomy, pharmacology and function of reward pathway. Trends Pharmacol Sci 1992; 13:177–184.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Weiss F. The dopamine hypothesis of reward: Past and current status. Trends Neurosci 1999; 22:521–527.
   PubMed Web of Science ®Google Scholar
• Amit Z, Smith BR, Gill K. Serotonin uptake inhibitors: Effects on motivated consummatory behaviors. J Clin Psychiatry 1991; 52:55–60.
   PubMed Web of Science ®Google Scholar
• Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: Implications for treatment. CNS Drugs 2004; 18(15):1105–1118.
   Google Scholar
• Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry 1997; 42:529–545.
   PubMed Web of Science ®Google Scholar
• Awad AG. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development? J Psychopharmacol 2012; 26(7):953–957.
   PubMed Web of Science ®Google Scholar
• Auclair AL, Galinier A, Besnard J, Newman TA, Depoortere R. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology (Berl) 2007; 193:45–54.
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381–389.
   PubMed Web of Science ®Google Scholar
• Fujikawa M, Nagashima M, Inoue T, Yamada K, Furukawa T. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 1996; 53:903–909.
   Google Scholar
• Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J. Psychopharmacol 2004; 18:375–383.
   PubMed Web of Science ®Google Scholar
• Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008; 28(1):5–12.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. naltrexone. J Psychopharmacol 2009; 23(2):123–129.
   PubMed Web of Science ®Google Scholar
• Kenna GA, Leggio L, Swift RM. A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Human Neuropsychopharmacol Clin Exp 2009; 24(6):465–472.
   Google Scholar
• Martinotti G, Nicola MD, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 2007; 33:393–401.
   PubMed Web of Science ®Google Scholar
• Voronin K, Randall P, Myrick H, Anton R. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm-possible influence of self-control. Alcohol Clin Exp Res 2008; 32(11):1954–1961.
   Google Scholar
• Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, Phebus LA. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radio labeled or nonlabeled raclopride tracer. Life Sci 2006; 78:3007–3012.
   PubMed Web of Science ®Google Scholar
• Chernet E, Martin LJ, Li D, Need AB, Barth VN, Rash KS, Phebus LA. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci 2005; 78:340–346.
   PubMed Web of Science ®Google Scholar
• Need AB, McKinzie JH, Mitch CH, Statnick MA, Phebus LA. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. Life Sci 2007; 81:1389–1396.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Kandikere V, Bhyrapuneni G, Muddana N, Saralaya R, Ponnamaneni RK, Manoharan AK. In vivo receptor occupancy assay of histamine H3 receptor antagonist in rats using non-radiolabeled tracer. J Pharmacol Toxicol Methods 2012; 65(3):115–121.
   Google Scholar
• Nirogi R, Kandikere V, Bhyrapuneni G, Saralaya R, Muddana N, Ajjala DR. Rat thalamic α4β2 neuronal nicotinic acetylcholine receptor occupancy assay using LC-MS/MS. J Pharmacol Toxicol Methods 2012; 65(3):136–141.
   Google Scholar
• Ingman K, Kupila J, Hyytia P, Korpi ER. Effect of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 2006; 41:391–398.
   PubMed Web of Science ®Google Scholar
• Falk JL, Tang M. What schedule-induced polydipsia can tell us about alcoholism. Alcohol Clin Exp Res 1988; 12(5):577–585.
   Google Scholar
• Grant KA, Leng X, Green HL, Szeliga KT, Rogers LS, Gonzales SW. Drinking typography established by scheduled induction predicts chronic heavy drinking in a monkey model of ethanol self-administration. Alcohol Clin Exp Res 2008; 32(10):1824–1838.
   Google Scholar
• Roehrs T & Roth T. Sleep, Sleepiness, and Alcohol Use. Alcohol Res. Health 2001; 25: 101–109.
   PubMedGoogle Scholar
• Shimokawa Y, Akiyama H, Kashiyama E, Koga T, Miyamoto G. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: Application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 821:8–14.
   Google Scholar
• Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10(4):317–336.
   PubMedGoogle Scholar
• Satoskar RS, Bhandarkar SD, Rege NN. Section II: Drugs acting on central nervous system, aliphatic alcohol–ethyl alcohol actions. In Pharmacology and Pharmacotherapeutics. Satoskar RS, Bhandarkar SD eds. Mumbai: Popular Prakashan Private Limited, 2009; 83–91.
   Google Scholar
• Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y. Alcohol induced oxidative stress in brain endothelial cells causes blood brain barrier dysfunction. J Leukoc Biol 2005; 78:1223–1232.
   PubMed Web of Science ®Google Scholar
• Haorah J, Heilman D, Knipe B, Chrastil J, Leibhart J, Ghorpade A, Miller DW, Persidsky Y. Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcoholism Clin Exp Res 2005; 29:999–1009.
   PubMed Web of Science ®Google Scholar
• Haorah J, Knipe B, Gorantla S, Zheng J, Persidsky Y. Alcohol-induced blood–brain barrier dysfunction is mediated via inositol 1,4,5-triphosphate receptor (IP3R)-gated intracellular calcium release. J Neurochem 2007; 100:324–336.
   PubMed Web of Science ®Google Scholar
• Singh A, Jiang Y, Gupta S, Benlhabib E. Effects of chronic ethanol drinking on the blood–brain barrier and ensuing neuronal toxicity in alcohol-preferring rats subjected to intraperitoneal LPS injection. Alcohol Alcohol 2007; 42(5):385–399.
   PubMed Web of Science ®Google Scholar
• Pratt OE, Rooprai HK, Shaw GK, Thomson AD. The genesis of alcoholic brain tissue injury. Alcohol Alcohol 1990; 25:217–230.
   Google Scholar
• Thomsen H, Kaatsch HJ, Asmus R. Magnetic resonance imaging of the brain during alcohol absorption and elimination a study of the “rising tide phenomenon”. Blutalkohol 1994; 31:178–185.
   PubMedGoogle Scholar
• Phillips SC, Cragg BG. Weakening of the blood–brain barrier by alcohol-related stresses in the rat. J Neurol Sci 1982; 54:271–278.
   Google Scholar
• Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31:1854–1863.
   PubMed Web of Science ®Google Scholar
• Natesan S, Reckless GE, Barlow KBL, Nobrega JN, Fletcher PJ, Kapur S. Partial agonists in schizophrenia – Why some work and others do not: Insights from preclinical animal models. Int J Neuropsychopharmacol 2011; 9:1165–78.
   Google Scholar
• Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71–76.
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514–520.
   PubMed Web of Science ®Google Scholar
• Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27:248–259.
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763–771.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. Aripiprazole an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681–690.
   PubMed Web of Science ®Google Scholar
• Sparshatt A, Taylor A, Patel MX, Kapur S. A systematic review of aripiprazole – Dose, plasma concentration, receptor occupancy, and response: Implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71:1447–1456.
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R. Differential effects of Aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry 2007; 164(9):1411–1417.
   Google Scholar
• European Medicines Agency. Scientific discussion for the approval of Abilify. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000471/WC500020164. pdf. Last accessed on July 7, 2012.
   Google Scholar
• Wallace C, Mullen PE, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry 2004; 161:716–727.
   PubMed Web of Science ®Google Scholar
• Swainston HT, Perry CM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64:1715–1736.
   PubMed Web of Science ®Google Scholar